The global metabolismdrugs market, by Therapy Type (Enzyme Replacement Therapy, SubstrateReduction Therapy, Small Molecule Drugs, and Others), by Application (GlycogenMetabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism Disease, andOthers), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, andOnline Pharmacies), and by Region (North America, Latin America, Europe, AsiaPacific, the Middle East, and Africa) was valued at US$ 5,765.3 million in2017, and is projected to exhibit a CAGR of 6.3% over the forecast period (2018– 2026).
Availability of wide number oftherapies such as small molecule drugs and enzyme replacement therapy,increasing prevalence of metabolic diseases, and robust pipeline is expected tofuel growth of the metabolism drugs market. Manufacturers are actively workingon developing new therapies for various metabolic diseases.
For instance, various pipelineproducts include NeoGAA GZ402666 (Sanofi) in phase 3, AT-982 in phase 3(Audentes Therapeutics)), and BMN 701 in phase 2 (BioMarin Pharmaceutical,Inc.) clinical trial are also expected to create a meteoric growth in thismarket during the forecast period. Amicus Therapeutics was granted with orphandrug designation for its investigational combination drug therapyATB200/AT2221, in November 2017. This drug is intended to cure Pompe disease(acid maltase deficiency or AMD). in March 2018, Shire plc entered into apreclinical research collaboration with NanoMedSyn— French biotech company—todevelop enzyme replacement treatment for a lysosomal storage disorder based onNanoMedSyn’s synthetic derivative technology named AMFA.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1955
Lixte Biotechnology Holdings,Inc., has LB-201/LB-205 in the preclinical stage, JCR Pharmaceuticals Co. Ltd.filed for JR-051 in Japan in 2017, and has many other products in the pipelinefor treatment of metabolic diseases. Moreover, manufacturers such as PharmingGroup NV and Orphazyme ApS also have products in the pipeline for metabolicdiseases.
Browse 34 Market Data Tables and43 Figures spread through 167 Pages and in-depth TOC on Metabolism DrugsMarket, by Therapy Type (Enzyme Replacement Therapy, Substrate ReductionTherapy, Small Molecule Drugs, and Others), by Application (Glycogen MetabolismDisease, Lipid Metabolism Disease, Amino Acid Metabolism Disease, and Others),By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and OnlinePharmacies), and by Region (North America, Latin America, Europe, Asia Pacific,the Middle East, and Africa) - Global Forecast to 2026
Partnerships and collaborationfrom individual organizations for research and development of effectivetherapies is expected to boost growth of the metabolism drugs market. Forinstance, in 2014, Shire Plc announced collaboration with ArmaGen to developAGT-182 drug for treatment of hunter syndrome. Moreover, in 2017, Researchfunded by the National Institute of Neurological Disorders and Stroke (NINDS)demonstrated that viral-delivered gene therapy can stop the buildup materialsstored in the brain cells and improve memory and learning. High return oninvestments, health insurance coverage, and various reimbursement policies forsuch costly drugs are influencing pharmaceutical companies to invest in drugdevelopment. For instance, in 2015, Orphan Product Grants Program funded 18 newgrant awards from 92 grant applications and provided funding and support toaround 67 ongoing clinical study projects related to rare disease.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/metabolism-drugs-market-1955
Furthermore, initiatives from thegovernments of economies such as Sweden, the Netherlands, and South Korea thatfocus on approving guidelines for the reimbursement of individuals undergoingenzyme replacement therapy (ERT) are also expected to boost growth of themetabolic drugs market (as enzyme replacement being major therapies in themarket) in the near future.
Key Takeaways of the MetabolismDrugs Market:
The global metabolism drugsmarket is expected to exhibit a CAGR of 3% over the forecast period (2018 –2026), owing to partnerships and collaboration for drug development by leadingmanufacturers such as Shire Plc
Enzyme replacement therapies areexpected to be the driving factor behind growth of the metabolism drugs market
North America is expected todominant position in the metabolism drugs market over the forecast period dueto active research and development activities by leading players in the region
Major players operating in theglobal metabolism drugs market include Merck & Co., Inc., Novartis AG,Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, SanofiGenzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKlinePlc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1955
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
